Figure 4.

Prognostic analysis of an immune prognostic model (IPM). All early‐stage lung adenocarcinoma (LUAD) cases were stratified into high‐ and low‐risk groups based on median risk score in (A–C) the TCGA training cohort and (D–F) the meta‐GEO testing cohort. (A and D) Kaplan–Meier curves revealed that individuals with high risk score displayed remarkably diminished overall survival (OS) than those with low risk score. (B and E) The risk score distribution was consistent with the heatmap of two immune‐related prognostic genes' expression and survival status of cases. The black dotted line signals the cutoff of IPM risk score to stratify cases into low‐ and high‐risk groups. (C and F) Time‐dependent ROC curves of the IPM demonstrated the relatively satisfactory predictive performance. (G and H) Prognostic prediction efficiency was evaluated between an IPM and 21‐gene signature as well as 8‐gene signature through estimating the C‐index in both cohorts